Serum NGAL in Critically Ill Children in ICU from a Single Center in Egypt

Table 3

Serum NGAL, urea, and creatinine at day zero and 3rd day among 2 groups of patients: AKI (group A) and NAKI (group B).

Parameters	AKI		Test of significance	𝑃
	Absent 𝑁=47	Present 𝑁=13
NGAL-0 (ng/mL)
Median	76	110	2.64^b	0.008*
Range	(34–200)	(66–210)
NGAL-3 (ng/mL)
Median	105	280	3.32^b	0.001*
Range	(34–530)	(92–550)
Urea-0 (mg/dL)
Median	34.5	42.5	2.04^b	0.040*
Range	(15–116)	(28.7–78.8)
Urea-3 (mg/dL)
Median	38	113.4	3.00^b	0.003*
Range	(18–310)	(7–228)
Creatinine-0 (mg/dL)
X ± SD	0.61 ± 0.23	0.86 ± 0.23	3.4^a	0.001*
Creatinine-3 (mg/dL)
X ± SD	0.73 ± 0.63	2.08 ± 1.24	10.1^a	0.000*

Test of significance: ^at-test; ^bMann-Whiney test; *significant.